Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.
Phase 2
- Conditions
- Previously Treated Metastatic Non-Small Cell Lung Cancer
- Registration Number
- NCT00238849
- Lead Sponsor
- Integrated Community Oncology Network
- Brief Summary
The purpose of this study is to determine the response rate to treatment with oxaliplatin and Navelbine in patients with previously treated NSCLC. Oxaliplatin and Navelbine have not been clinically evaluated yet. However, Navelbine has been safely administered with other platinum compounds.
- Detailed Description
This is a non-randomized trial for patients with previously treated Non-small cell lung cancer. Each patient will receive 6 cycles of chemotherapy consisting of Oxaliplatin and Navelbine. Oxaliplatin is given intravenously every 21 days and Navelbine is administered Intravenously on day 1 and day 8 every 21 days.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Locally advanced or metastatic non-small cell lung cancer that has recurred, progressed, or failed to respond to previous systemic chemo.
- Measurable disease
- Good performance status (ECOG 0,1 or 2)
Exclusion Criteria
- Previously treated with Oxaliplatin or Navelbine
- Symptomatic CNS metastases
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Efficacy
- Secondary Outcome Measures
Name Time Method Time to progression Duration of response Survival Toxicity profile
Trial Locations
- Locations (1)
Integrated Community Oncology Network
🇺🇸Orange Park, Florida, United States